home / stock / snoa / snoa news

SNOA News and Press, Sonoma Pharmaceuticals Inc. From 04/09/24

Stock Information
Company Name: Sonoma Pharmaceuticals Inc.
Stock Symbol: SNOA
Market: NASDAQ
Website: sonomapharma.com
Menu
SNOA SNOA Quote SNOA Short SNOA News SNOA Articles SNOA Message Board
Get SNOA Alerts

News, Short Squeeze, Breakout and More Instantly...
SNOA - Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States

BOULDER, CO / ACCESSWIRE / April 9, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasa...
SNOA - Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections

BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal ...

SNOA - Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences

BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal...

SNOA - Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals

BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care and dermatologi...
SNOA - Sonoma Pharmaceuticals GAAP EPS of -$0.08 beats by $0.13, revenue of $3.14M misses by $0.62M

2024-02-08 17:22:43 ET More on Sonoma Pharmaceuticals Seeking Alpha’s Quant Rating on Sonoma Pharmaceuticals Historical earnings data for Sonoma Pharmaceuticals Financial information for Sonoma Pharmaceuticals Read the full article on Seeking Alpha ...

SNOA - Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results

Revenues increased 7% compared to quarter from prior year and 15% from prior quarter Improvement in gross margin for quarter of 19% compared to prior year Improvement in net loss for quarter of $1.0 million compared to prior year BOULDER, CO / ACCESSWIRE / February 8, 2024 / Sonom...

SNOA - Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use

BOULDER, CO / ACCESSWIRE / January 23, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, today announced the launch of Lu...
SNOA - NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network

EMERYVILLE, CA and BOULDER, CO / ACCESSWIRE / January 9, 2024 / NovaBay Pharmaceuticals, Inc. (NYSE American:NBY) and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova ® -branded products by Sonoma in the European Union. The new pr...

SNOA - Sonoma Pharmaceuticals GAAP EPS of -$0.29 misses by $0.05, revenue of $2.73M misses by $0.75M

2023-11-14 01:37:04 ET More on Sonoma Pharmaceuticals Seeking Alpha’s Quant Rating on Sonoma Pharmaceuticals Historical earnings data for Sonoma Pharmaceuticals Financial information for Sonoma Pharmaceuticals For further details see: Sonoma Pharma...

SNOA - Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results

Gross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024 Total operating expenses decreased for the quarter and six months ended September 30, 2023 compared to same period prior year European revenues increased 3% for the quarter and 13% for the six months ended ...
Previous 10 Next 10